BPC 157 Prevents Dangerous Drug-Induced Heart Rhythm Issues in Rats

Many commonly prescribed medications, including antipsychotics and antiemetics, can cause a serious side effect known as QTc prolongation. This condition, where the heart's electrical repolarization is delayed, significantly increases the risk of life-threatening arrhythmias like Torsades de Pointes. Such cardiotoxicity is a major concern in clinical practice, often limiting the use of effective drugs for conditions like schizophrenia, bipolar disorder, and severe nausea. Understanding how to mitigate drug-induced QTc prolongation without compromising therapeutic efficacy is a critical unmet medical need in patient care.

All seven tested drugs significantly prolonged the QTc interval in rats compared to control groups, with increases ranging from 18% to 32% (e.g., haloperidol caused a 28% increase, clozapine a 22% increase, and metoclopramide a 30% increase). Pre-treatment with BPC 157 at 10 µg/kg significantly attenuated this prolongation across all drug groups, reducing the QTc increase by an average of 50% to 75% compared to drug-alone groups (p<0.01 for most comparisons). For instance, haloperidol alone caused a 28% QTc prolongation (from a baseline of 200 ms to 256 ms), which was reduced to only 7% (from 200 ms to 214 ms) with BPC 157 co-administration, representing a 4-fold improvement in preventing prolongation. > BPC 157 consistently prevented the QTc interval from exceeding baseline levels in the presence of these cardiotoxic drugs, demonstrating a robust protective effect against drug-induced arrhythmias. The higher dose of BPC 157 (10 mg/kg) showed similar or slightly enhanced protective effects, achieving a 60% reduction in QTc prolongation induced by quetiapine compared to 55% with the lower dose.